Motor Neuron Disease Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight's, "Motor Neuron Disease Pipeline Insight 2026" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Motor Neuron Disease pipeline landscape. It covers the Motor Neuron Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Motor Neuron Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight's comprehensive Motor Neuron Disease Pipeline Report @ https://www.delveinsight.com/sample-request/motor-neuron-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Motor Neuron Disease Pipeline Report
• On July 29, 2026- Prilenia conducted a phase 3 study consisting of a double-blind placebo-controlled (DBPC) period followed by an open-label extension (OLE) to evaluate the efficacy and safety of pridopidine administered orally at a dose of 45 mg twice a day in adult participants with early and rapidly progressing ALS. Standard of care treatments (e.g. riluzole, edaravone and Nuedexta) will be allowed as long as participants are on a stable dose for at least 4 weeks prior to dosing. In the DBPC period, participants will be randomized in a 3:2 ratio to the pridopidine and placebo arms.
• On July 28, 2026- Zydus Therapeutics Inc. highlighted a phase 2b study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis followed by 16 weeks open label extension study.
• On July 22, 2026- Regeneron Pharmaceuticals initiated a study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be given to people.
• DelveInsight's Motor Neuron Disease pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Motor Neuron Disease treatment.
• The leading Motor Neuron Disease Companies such as Ionis Pharmaceuticals, Coya Therapeutics, Revalesio Corporation, VectorY Therapeutics, Eli Lilly and Company, ProJenX, Seelos Therapeutics, Time Therapeutics, SOLA Biosciences, Ceregene, ProMIS Neurosciences, Immunity Pharma Ltd., NervGen Pharma Corp., Dewpoint Therapeutics, MediciNova, Eledon Pharmaceuticals, SineuGene Therapeutics, Tiziana Life Sciences, Xalud Therapeutics, Inc., Cellenkos, AL-S Pharma, Gemma Biotherapeutics, Ractigen Therapeutics, Neurizon Therapeutics, Alcyone Therapeutics, UniQure N.V., Verge Genomics, 1st Biotherapeutics, Leal Therapeutics, Eikonizo Therapeutics and others.
• Promising Motor Neuron Disease Pipeline Therapies such as Trimetazidine Dihydrochloride, MD1003, Levetiracetam, Tocilizumab, AMX0035, 3K3A-APC Protein, GM604 and others.

Access DelveInsight's in-depth Motor Neuron Disease Pipeline Analysis for a closer look at promising breakthroughs @ https://www.delveinsight.com/sample-request/motor-neuron-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Motor Neuron Disease Pipeline Report provides a disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Motor Neuron Disease Pipeline Report also highlights the unmet needs with respect to Motor Neuron Disease.

Motor Neuron Disease Overview
Motor neuron disease (MND) is a progressive neurodegenerative disorder characterized by the degeneration of upper and lower motor neurons, leading to muscle weakness, wasting, cramps, and paralysis. The most common form is Amyotrophic Lateral Sclerosis, alongside other subtypes such as Progressive bulbar palsy, Progressive muscular atrophy, Primary lateral sclerosis, and Spinal muscular atrophy. Most cases are sporadic, although a subset is associated with inherited genetic mutations. Clinically, MND presents with early symptoms such as limb weakness, muscle twitching, and speech difficulties, which progressively evolve into impaired mobility, swallowing, and respiratory function. In addition to motor decline, patients often experience non-motor symptoms including pain, fatigue, sleep disturbances, mood changes, and cognitive impairment, all of which worsen with disease progression. Diagnosis is primarily clinical, supported by electrophysiological tests and imaging, while management focuses on symptomatic treatment, supportive care, and available disease-modifying therapies.

Motor neuron disease Emerging Drugs Profile
• Ulefnersen: Ionis Pharmaceuticals/ Otsuka Pharmaceutical
Ulefnersen (formerly ION-363, also known as Jacifusen) is an investigational antisense oligonucleotide (ASO) therapy being developed for the treatment of Amyotrophic Lateral Sclerosis associated with mutations in the FUS gene. The therapy is designed to selectively reduce the production of toxic FUS protein, a key driver of motor neuron degeneration in this genetic subtype of ALS. Preclinical evidence has demonstrated that suppression of FUS expression can prevent motor neuron loss in disease models. By targeting the underlying genetic cause, ulefnersen aims to slow or potentially halt disease progression in patients with FUS-related ALS. The candidate is currently in Phase III clinical development for the treatment of ALS.

• COYA 302: Coya Therapeutics
COYA 302 is an investigational biologic combination therapy being developed for the treatment of Amyotrophic Lateral Sclerosis. It comprises a proprietary low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, administered subcutaneously. The therapy is designed to enhance regulatory T-cell (Treg)-mediated anti-inflammatory activity while concurrently suppressing activated monocytes and macrophages. Through this dual mechanism, COYA 302 aims to restore immune balance and mitigate chronic neuroinflammation associated with ALS progression. The candidate is currently in Phase II clinical development.

• RNS60: Revalesio Corporation
RNS60 is an investigational, oxygen-enriched saline formulation being developed as a potential disease-modifying and restorative therapy for neurological disorders, including Amyotrophic Lateral Sclerosis. The therapy is designed to enhance mitochondrial biogenesis, improve cellular energy metabolism, and reduce inflammation, thereby protecting neurons and oligodendrocytes while modulating immune responses to restore physiological balance. Supported by robust preclinical evidence, RNS60 has been granted Orphan Drug and Fast Track designations by the US Food and Drug Administration for ALS. The drug is currently in Phase II development for the treatment of Amyotrophic Lateral Sclerosis.

• Tegoprubart: Eledon Pharmaceuticals
Tegoprubart (formerly AT-1501), developed by Eledon Pharmaceuticals, is an investigational humanized monoclonal antibody being evaluated for the treatment of Amyotrophic Lateral Sclerosis. The therapy targets CD40 Ligand (CD40L), a key regulator of immune cell activation and neuroinflammatory signaling. By inhibiting CD40L, tegoprubart is designed to suppress neuroinflammatory processes implicated in ALS pathogenesis, thereby potentially slowing disease progression. The candidate is currently in Phase II clinical development.

• VTx-002: VectorY Therapeutics
VTx-002 is an investigational small-molecule therapy being developed for the treatment of Amyotrophic Lateral Sclerosis. It is designed to selectively modulate immune signaling pathways implicated in neuroinflammation, a key driver of motor neuron degeneration in ALS. By targeting specific immune mediators, VTx-002 aims to reduce inflammatory responses and protect neuronal integrity. The therapy is expected to help preserve motor function and slow disease progression through its immunomodulatory mechanism. Currently, VTx-002 is in Phase I/II stage of its development for ALS.

• SNUG01: SineuGene Therapeutics
SNUG01, developed by SineuGene Therapeutics, is a first-in-class gene therapy being investigated for the treatment of Amyotrophic Lateral Sclerosis. The therapy utilizes a recombinant adeno-associated virus serotype 9 (rAAV9) vector to deliver the human TRIM72 gene to neurons via intrathecal administration. TRIM72 is associated with multiple neuroprotective effects, including reduction of oxidative stress, restoration of mitochondrial function, suppression of neuroinflammation, and promotion of neuronal membrane repair. Through these mechanisms, SNUG01 aims to slow disease progression, particularly in patients with sporadic ALS, which represents the majority of cases. The candidate is currently in Phase I/II clinical development.

• LY4256984: Eli Lilly and Company
LY4256984, developed by Eli Lilly and Company, is an investigational biologic being evaluated for the treatment of Amyotrophic Lateral Sclerosis and other neurodegenerative disorders. It is designed to target and modulate neuroinflammatory pathways implicated in motor neuron degeneration by inhibiting key immune mediators involved in neuronal injury. Through this mechanism, the therapy aims to reduce inflammation-driven neurotoxicity and preserve motor function. With its novel immunomodulatory approach, LY4256984 represents a potential next-generation strategy for slowing disease progression in ALS and related conditions. The drug is in Phase I stage of its clinical trial for the treatment of amyotrophic lateral sclerosis.

Get a detailed analysis of the latest innovations in the Motor Neuron Disease pipeline @ https://www.delveinsight.com/sample-request/motor-neuron-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Motor Neuron Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Motor Neuron Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Motor Neuron Disease Treatment.
• Motor Neuron Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Motor Neuron Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Motor Neuron Disease market.

Motor Neuron Disease Companies
Ionis Pharmaceuticals, Coya Therapeutics, Revalesio Corporation, VectorY Therapeutics, Eli Lilly and Company, ProJenX, Seelos Therapeutics, Time Therapeutics, SOLA Biosciences, Ceregene, ProMIS Neurosciences, Immunity Pharma Ltd., NervGen Pharma Corp., Dewpoint Therapeutics, MediciNova, Eledon Pharmaceuticals, SineuGene Therapeutics, Tiziana Life Sciences, Xalud Therapeutics, Inc., Cellenkos, AL-S Pharma, Gemma Biotherapeutics, Ractigen Therapeutics, Neurizon Therapeutics, Alcyone Therapeutics, UniQure N.V., Verge Genomics, 1st Biotherapeutics, Leal Therapeutics, Eikonizo Therapeutics and others.

Motor Neuron Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Motor Neuron Disease Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming Motor Neuron Disease Therapies @ https://www.delveinsight.com/sample-request/motor-neuron-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Motor Neuron Disease Pipeline Report
• Coverage- Global
• Motor Neuron Disease Companies- Ionis Pharmaceuticals, Coya Therapeutics, Revalesio Corporation, VectorY Therapeutics, Eli Lilly and Company, ProJenX, Seelos Therapeutics, Time Therapeutics, SOLA Biosciences, Ceregene, ProMIS Neurosciences, Immunity Pharma Ltd., NervGen Pharma Corp., Dewpoint Therapeutics, MediciNova, Eledon Pharmaceuticals, SineuGene Therapeutics, Tiziana Life Sciences, Xalud Therapeutics, Inc., Cellenkos, AL-S Pharma, Gemma Biotherapeutics, Ractigen Therapeutics, Neurizon Therapeutics, Alcyone Therapeutics, UniQure N.V., Verge Genomics, 1st Biotherapeutics, Leal Therapeutics, Eikonizo Therapeutics and others.
• Motor Neuron Disease Pipeline Therapies- Trimetazidine Dihydrochloride, MD1003, Levetiracetam, Tocilizumab, AMX0035, 3K3A-APC Protein, GM604 and others.
• Motor Neuron Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Motor Neuron Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight's exclusive Motor Neuron Disease Pipeline Report @ https://www.delveinsight.com/sample-request/motor-neuron-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Introduction
2. Executive Summary
3. Motor Neuron Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Motor Neuron Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Ulefnersen: Ionis Pharmaceuticals / Otsuka Pharmaceutical
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. COYA 302: Coya Therapeutics
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. LY4256984: Eli Lilly and Company
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Motor Neuron Disease Key Companies
21. Motor Neuron Disease Key Products
22. Motor Neuron Disease- Unmet Needs
23. Motor Neuron Disease- Market Drivers and Barriers
24. Motor Neuron Disease- Future Perspectives and Conclusion
25. Motor Neuron Disease Analyst Views
26. Motor Neuron Disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.